Cancer Metabolism: Partners in the Warburg effect

  1. Joshua D Rabinowitz  Is a corresponding author
  2. Hilary A Coller
  1. Princeton University, United States
  2. University of California, Los Angeles, United States
  3. David Geffen School of Medicine, United States

In 1918 Albert Einstein convinced Otto Warburg to leave the German infantry and fulfill his patriotic requirements in the first World War by performing research instead (Koppenol et al., 2011). Back in the lab at the Kaiser Wilhelm Institute, Warburg discovered that thin slices of tumors produced lactate much more rapidly than normal tissue. This rapid fermentation of glucose by tumors, even in the presence of ample oxygen, was the first biochemical trait assigned to cancer and is known as the Warburg effect.

When oxygen is present, most human cells rely on a process called oxidative phosphorylation inside mitochondria to convert lactate into carbon dioxide and usable energy. Warburg proposed that the rapid glucose fermentation and associated lactate secretion by the cancer cells was due to mitochondrial dysfunction. However, subsequent studies have shown that most cancer cells do have working mitochondria and, moreover, depend heavily upon them to produce energy (Zu and Guppy, 2004Moreno-Sánchez et al., 2007). Instead of causing mitochondrial dysfunction, it was found that the mutations that cause cancer also promote the breakdown of glucose in a process called glycolysis. The most striking example involves the PI3K-Akt signaling pathway, which both transduces the signal from the hormone insulin to drive glucose uptake, and is one of the most frequently mutated pathways in cancer. One way this pathway can be activated is by the loss of a tumor suppressing enzyme called PTEN (Shaw and Cantley, 2006). The observation of oncogene-driven glucose uptake seemed to neatly explain the Warburg effect.

Over the past few decades, evidence has steadily accumulated that cancer cells also hijack surrounding cells (Cirri and Chiarugi, 2012). For example, cancer cells secrete growth factors to promote the formation of new blood vessels (Orimo et al., 2005), which are required to supply tumors with nutrients. Moreover, they co-opt surrounding connective tissue cells, including fibroblasts, which exchange signals with the cancer cells in a manner that ultimately drives tumor growth and likely helps to suppress immune responses to the tumor (Cirri and Chiarugi, 2012). However, both the mechanism of this exchange and its role in tumor growth remain poorly understood.

Fibroblasts may exchange both signaling molecules and metabolic fuels with the cancer cells, either by secreting individual molecules (e.g. lactate; Martinez-Outschoorn et al., 2014) or by releasing membrane-bound vesicles known as exosomes (Castellana et al., 2009). For example, recent work has shown that the spread of cancer in the brain is promoted by the exosomes that are released by a particular type of brain cell. These exosomes contain small RNA molecules known as microRNAs that can silence the gene that encodes the PTEN enzyme, whose loss drives an increase in glycolysis (Zhang et al., 2015).

Now, in eLife, Deepak Nagrath at Rice University and colleagues – including Hongyun Zhao as first author – show that cancer-associated fibroblasts release exosomes that both deliver nutrients to cancer cells and inhibit oxidative phosphorylation (Zhao et al., 2016; Figure 1). Zhao et al. use isotope-labelled carbon compounds to provide compelling evidence that exosomes from fibroblasts can supply an amino acid called glutamine and other nutrients to cancer cells. A shortage of glutamine can limit the growth of pancreatic and perhaps other cancers (Kamphorst et al., 2015). Importantly, although the exosomes contribute modest amounts of nutrients, they can protect cancer cells from starvation, hinting at one potential role for such metabolic exchange in tumors.

More striking and surprising is the role of the exosomes in causing the Warburg effect. Adding exosomes to prostate or pancreatic cancer cells both promotes glycolysis and blocks oxidative metabolism. It is likely that the increase in glycolysis is caused by the reduction in oxidative phosphorylation so, in this respect, the exosomes trigger glycolysis in the way initially envisioned by Warburg. These results call for a re-examination of the contributions of both processes to energy generation in cancer cells that are still associated with their neighbors.

Such re-examination is particularly important given that oxidative phosphorylation is reduced so dramatically in cancer cells, with oxygen consumption lowered by up to 80% within 24 hours of receiving exosomes from fibroblasts. Zhao et al. – who are based at Rice University, Baylor College of Medicine, the University of Texas MD Anderson Cancer Center and Stanford University – propose that the exosomes may deliver microRNAs that silence oxidative metabolism genes, but this is hard to reconcile with the timing. Since the proteins involved in oxidative phosphorylation are generally long-lived, even complete inhibition of their production seems unlikely to produce such drastic effects so quickly. Nor can the decreased oxidative phosphorylation be explained by the delivery of nutrients by exosomes, because increasing the access to such nutrients would be expected to promote, not inhibit, the use of oxygen. Thus, understanding how the exosomes inhibit oxidative phosphorylation is a key challenge going forward. Such work holds the potential to illuminate not only the Warburg effect, but also the regulation of oxidative phosphorylation in cells more generally.

Fibroblasts supply nutrients to cancer cells and inhibit oxidative phosphorylation in cancer cells.

Fibroblasts (pink cells) associate with epithelial cancer cells (blue cells) and release exosomes (circles) that transfer nutrients to epithelial cancer cells (orange lines). In addition, they inhibit mitochondrial oxidative phosphorylation in the cancer cells (black blunt arrows), perhaps via microRNAs that silence particular genes.

References

    1. Zu XL
    2. Guppy M
    (2004) Cancer metabolism: Facts, fantasy, and fiction
    Biochemical and Biophysical Research Communications 313:459–465.
    https://doi.org/10.1016/j.bbrc.2003.11.136

Article and author information

Author details

  1. Joshua D Rabinowitz

    Department of Chemistry and the Lewis Sigler Institute for Integrative Genomics, Princeton University, Princeton, United States
    For correspondence
    joshr@princeton.edu
    Competing interests
    The authors declare that no competing interests exist.
  2. Hilary A Coller

    1. Department of Molecular, Cell and Developmental Biology, University of California, Los Angeles, Los Angeles, United States
    2. Department of Biological Chemistry, David Geffen School of Medicine, Los Angeles, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0992-6494

Publication history

  1. Version of Record published:

Copyright

© 2016, Rabinowitz et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,621
    views
  • 822
    downloads
  • 10
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Joshua D Rabinowitz
  2. Hilary A Coller
(2016)
Cancer Metabolism: Partners in the Warburg effect
eLife 5:e15938.
https://doi.org/10.7554/eLife.15938

Further reading

    1. Cell Biology
    2. Neuroscience
    Jun Sun, Francisca Rojo-Cortes ... Alicia Hidalgo
    Research Article

    Experience shapes the brain as neural circuits can be modified by neural stimulation or the lack of it. The molecular mechanisms underlying structural circuit plasticity and how plasticity modifies behaviour are poorly understood. Subjective experience requires dopamine, a neuromodulator that assigns a value to stimuli, and it also controls behaviour, including locomotion, learning, and memory. In Drosophila, Toll receptors are ideally placed to translate experience into structural brain change. Toll-6 is expressed in dopaminergic neurons (DANs), raising the intriguing possibility that Toll-6 could regulate structural plasticity in dopaminergic circuits. Drosophila neurotrophin-2 (DNT-2) is the ligand for Toll-6 and Kek-6, but whether it is required for circuit structural plasticity was unknown. Here, we show that DNT-2-expressing neurons connect with DANs, and they modulate each other. Loss of function for DNT-2 or its receptors Toll-6 and kinase-less Trk-like kek-6 caused DAN and synapse loss, impaired dendrite growth and connectivity, decreased synaptic sites, and caused locomotion deficits. In contrast, over-expressed DNT-2 increased DAN cell number, dendrite complexity, and promoted synaptogenesis. Neuronal activity modified DNT-2, increased synaptogenesis in DNT-2-positive neurons and DANs, and over-expression of DNT-2 did too. Altering the levels of DNT-2 or Toll-6 also modified dopamine-dependent behaviours, including locomotion and long-term memory. To conclude, a feedback loop involving dopamine and DNT-2 highlighted the circuits engaged, and DNT-2 with Toll-6 and Kek-6 induced structural plasticity in this circuit modifying brain function and behaviour.

    1. Cell Biology
    Xue Yang, Chuyi Han ... Fanyuan Yu
    Research Article

    Platelet-derived growth factor receptor alpha (PDGFR-α) activity is crucial in the process of dental and periodontal mesenchyme regeneration facilitated by autologous platelet concentrates (APCs), such as platelet-rich fibrin (PRF), platelet-rich plasma (PRP) and concentrated growth factors (CGF), as well as by recombinant PDGF drugs. However, it is largely unclear about the physiological patterns and cellular fate determinations of PDGFR-α+ cells in the homeostasis maintaining of adult dental and periodontal mesenchyme. We previously identified NFATc1 expressing PDGFR-α+ cells as a subtype of skeletal stem cells (SSCs) in limb bone in mice, but their roles in dental and periodontal remain unexplored. To this end, in the present study we investigated the spatiotemporal atlas of NFATc1+ and PDGFR-α+ cells residing in dental and periodontal mesenchyme in mice, their capacity for progeny cell generation, and their inclusive, exclusive and hierarchical relations in homeostasis. We utilized CRISPR/Cas9-mediated gene editing to generate two dual recombination systems, which were Cre-loxP and Dre-rox combined intersectional and exclusive reporters respectively, to concurrently demonstrate the inclusive, exclusive, and hierarchical distributions of NFATc1+ and PDGFR-α+ cells and their lineage commitment. By employing the state-of-the-art transgenic lineage tracing techniques in cooperating with tissue clearing-based advanced imaging and three-dimensional slices reconstruction, we systematically mapped the distribution atlas of NFATc1+ and PDGFR-α+ cells in dental and periodontal mesenchyme and tracked their in vivo fate trajectories in mice. Our findings extend current understanding of NFATc1+ and PDGFR-α+ cells in dental and periodontal mesenchyme homeostasis, and furthermore enhance our comprehension of their sustained therapeutic impact for future clinical investigations.